Safety and efficacy of the switch to generic mycophenolate mofetil and tacrolimus in heart-transplant patients.

Carl Söderlund, Göran Rådegran

Research output: Contribution to journalArticlepeer-review

3 Citations (SciVal)

Abstract

Generic immunosuppressants may offer economic advantages, but their use is still controversial. At our centre, 55 heart-transplant patients were switched from CellCept(®) to Myfenax Teva(®) (MT) (n=51, 18% female, 8.1±6.6 years post-transplantation) and/or Prograf(®) to Tacrolimus Sandoz(®) (TS) (n=17, 41% female, 6.6±5.8 years post-transplantation).
Original languageEnglish
Pages (from-to)619-628
JournalClinical Transplantation
Volume29
Issue number7
DOIs
Publication statusPublished - 2015

Subject classification (UKÄ)

  • Cardiac and Cardiovascular Systems

Fingerprint

Dive into the research topics of 'Safety and efficacy of the switch to generic mycophenolate mofetil and tacrolimus in heart-transplant patients.'. Together they form a unique fingerprint.

Cite this